⌘K
Glox Therapeutics
Healthcare & Life Sciences
Recent Finacing
Non-dilutive financing
Recent Raise
$0.6M
Glox Therapeutics develops precision antibiotics targeting drug-resistant bacteria, with a focus on creating high-potency bacteriocins to selectively target and kill antibiotic-resistant Gram-negative pathogens while preserving the patient's microbiome.
Total Funding
$7.199999999999999M
Headquarters
Glasgow, United Kingdom
Founded
2023
Website
Focus Areas
Biotech
Precision Antibiotics
Drug-Resistant Bacteria
Bacteriocin Development
Gram-Negative Pathogens
Microbiome Preservation
Investors
